Adaptimmune

About Adaptimmune

Adaptimmune is a pioneering biotechnology company based in the UK, dedicated to the development of innovative T-cell therapies for cancer treatment. The company focuses on harnessing the power of the immune system to target and eliminate cancer cells, offering hope to patients with various types of malignancies.

Founded in 2008, Adaptimmune has established itself as a leader in the field of cell therapy, particularly in the area of engineered T-cell receptors (TCRs). These TCRs are designed to recognize and attack specific cancer antigens, providing a tailored approach to cancer treatment.

The company’s flagship product, ADP-A2M4, is currently in clinical trials and has shown promising results in treating patients with solid tumours. Adaptimmune is committed to advancing its pipeline of therapies, with several candidates in various stages of development.

Adaptimmune operates with a vision to transform cancer care through its cutting-edge research and development efforts. The company collaborates with leading academic institutions and industry partners to enhance its therapeutic offerings and expand its reach.

With a strong emphasis on scientific excellence, Adaptimmune invests heavily in research and development, ensuring that it remains at the forefront of immunotherapy advancements. The company’s team comprises highly skilled professionals with extensive experience in oncology, immunology, and biotechnology.

Adaptimmune is headquartered in Oxford, UK, and is publicly traded on the NASDAQ under the ticker symbol ADAP. The company is committed to maintaining high ethical standards and transparency in its operations, fostering trust among stakeholders and the communities it serves.

As part of its corporate social responsibility, Adaptimmune actively engages in initiatives aimed at improving patient access to innovative therapies and supporting cancer research initiatives globally.

In summary, Adaptimmune is not just a biotechnology company; it is a beacon of hope for cancer patients, striving to make a significant impact in the fight against cancer through its innovative T-cell therapies.